Jia-Horng Kao, MD, PhD
National Taiwan University Hospital
10
5
4
N/A
0
0
Research Impact
N/A
Research impact score
0
Total publications
0
Published trial results
0
Total citations
Drug Portfolio
+8 more interventions
Analytics
Trial Phases
Trial Status
Role Distribution
Activity Timeline
Clinical Trials (10)
Research Network
Collaboration Network
Research Areas & Affiliations
Therapeutic Areas
Affiliations
Similar Key Opinion Leaders
Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.
Chen-Hua Liu, MD
National Taiwan University Hospital
Shared therapeutic areas:
Worked with same sponsors:
Cheng-Chao Liang, MD
Far Eastern Memorial Hospital
Shared therapeutic areas:
Worked with same sponsors:
Shih-Jer Hsu, MD
National Taiwan University Hospital, Yun-Lin Branch
Shared therapeutic areas:
Worked with same sponsors:
Peir-Haur Hung, MD
Chiayi Christian Hospital
Shared therapeutic areas:
Worked with same sponsors:
Shih-Jer Hsu, MD
National Taiwan University Hosptial, Yun-Lin Branch
Shared therapeutic areas:
Worked with same sponsors:
Chih-Lin Lin, MD
Ren-Ai Branch, Taipei City Hospital
Shared therapeutic areas:
Worked with same sponsors:
Ching-Sheng Hsu, MD
Buddhist Tzu Chi General Hospital
Shared therapeutic areas:
Worked with same sponsors:
Chun-Jen Liu, MD, PhD
National Taiwan University Hospital
Shared therapeutic areas:
Worked with same sponsors:
Ding-Shinn Chen, MD
National Taiwan University Hospital
Shared therapeutic areas:
Worked with same sponsors:
Chih-Lin Lin, MD, BS
Taipei Municipal Hospital, Ren-Ai Branch
Shared therapeutic areas:
Worked with same sponsors:
Publications (0)
No publications found for this investigator.
Clinical Trials (10)
Showing 10 of 10 trials
Evaluate the Efficacy and Safety of HLX10 in Chronic Hepatitis B Patients
Randomized Trial of 24 or 48 Weeks of Peginterferon Alfa-2a Plus Ribavirin for HCV Genotype 1-infected Patients
Peginterferon Alfa-2a and Ribavirin for Genotype 2 Chronic Hepatitis C: Duration and Ribavirin Dose Stratified by RVR
Early Prediction of Successful Treatment for Chronic Hepatitis C Virus Infection in Taiwan
Pegylated Interferon Alfa-2a for Dialysis Patients With Acute Hepatitis C
Entecavir and Pegasys Sequential Therapy Versus Pegasys for HBeAg Negative Chronic Hepatitis B
Entecavir and Pegasys Sequential Therapy Versus Pegasys for HBeAg Positive Chronic Hepatitis B
Double Filtration Plasmapheresis for Hepatitis C Virus (HCV) Genotype 1 Patients With High Viral Load
Clinical Performance of Abbott RealTime Hepatitis C Virus (HCV) Genotype II Test
Micro RNA-122 and the Clinical Course of Patients With Chronic Hepatitis C
All 10 trials loaded